High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza

Clinical and Vaccine Immunology

Volumn 19, Issue 7, 2012, Pages 1012-1018

  To, Kelvin K W ^a,b   Zhang, Anna J X ^a,b   Hung, Ivan F N ^a   Xu, Ting ^a   Ip, Whitney C T ^a   Wong, Rebecca T Y ^a   Ng, Joseph C K ^a   Chan, Jasper F W ^a   Chan, Kwok Hung ^a   Yuen, Kwok Yung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INFLUENZA VACCINE; NONNEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLUENZA A; MAJOR CLINICAL STUDY; MALE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; VIRION; VIRUS NEUTRALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIGENS, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE; SEVERITY OF ILLNESS INDEX;

EID: 84863558273     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00081-12     Document Type: Article

References (53)

1. Beebe DP, Schreiber RD, Cooper NR. 1983. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J. Immunol. 130:1317-1322. (Pubitemid 13159874)
2. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. 2008. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 181:4168-4176.
3. Casadevall A, Pirofski LA. 2011. A new synthesis for antibody-mediated immunity. Nat. Immunol. 13:21-28.
4. Chaloupka I, Schuler A, Marschall M, Meier-Ewert H. 1996. Comparative analysis of six European influenza vaccines. Eur. J. Clin. Microbiol. Infect. Dis. 15:121-127. (Pubitemid 26098745)
5. Chan JF, et al. 2011. The lower serum immunoglobulin G2 level in severe cases than in mild cases of pandemic H1N1 2009 influenza is associated with cytokine dysregulation. Clin. Vaccine Immunol. 18:305-310.
6. Chan KH, et al. 2011. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin. Vaccine Immunol. 18:867-873.
7. Chan KH, et al. 2010. Wild type and mutant 2009 pandemic influenza A (H1N1) viruses cause more severe disease and higher mortality in pregnant BALB/c mice. PLoS One 5:e13757. doi:10.1371/journal. pone.0013757.
8. Chen H, et al. 2010. Quasispecies of the D225G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009 virus from patients with severe disease in Hong Kong, China. J. Infect. Dis. 201:1517-1521.
9. Ehrhardt C, et al. 2010. Interplay between influenza A virus and the innate immune signaling. Microbes Infect. 12:81-87.
10. El Bakkouri K, et al. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186:1022-1031.
11. ElHefnawi M, et al. 2011. Identification of novel conserved functional motifs across most influenza A viral strains. Virol. J. 8:44.
12. European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP). 1997. Note for guidance on harmonization of requirements for influenza vaccines. EMEA, London, United Kingdom.
13. Gerin JL, Anderson NG. 1969. Purification of influenza virus in the K-II zonal centrifuge. Nature 221:1255-1256.
14. Guo X, et al. 2011. Dynamic variations in the peripheral blood lymphocyte subgroups of patients with 2009 pandemic H1N1 swine-origin influenza A virus infection. Virol. J. 8:215.
15. Hancock K, et al. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361:1945-1952.
16. Hung IF, Levin Y, To KK. 2012. Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine 30:2707-2708.
17. Hung IF, et al. 2010. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin. Infect. Dis. 51:274-279.
18. Khurana S, Verma N, Talaat KR, Karron RA, Golding H. 2012. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J. Infect. Dis. 205:610-620.
19. Kiraly J, Vareckova E, Mucha V, Kostolansky F. 2011. Evaluation of anti-influenza efficiency of polyclonal IgG antibodies specific to the ectodomain of M2 protein of influenza A virus by passive immunization of mice. Acta Virol. 55:261-265.
20. Krejnusova I, et al. 2009. Antibodies to PB1-F2 protein are induced in response to influenza A virus infection. Arch. Virol. 154:1599-1604.
21. LaMere MW, et al. 2011. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186:4331-4339.
22. Lapinsky SE. 2010. Critical illness as a result of influenza A/H1N1 infection in pregnancy. BMJ 340:c1235. doi:10.1136/bmj.c1235.
23. Liu W, et al. 2010. Clinical and immunological characteristics of patients with 2009 pandemic influenza A (H1N1) virus infection after vaccination. Clin. Infect. Dis. 51:1028-1032.
24. Louie JK, et al. 2011. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin. Infect. Dis. 52:301-312.
25. Lynch GW, Selleck P, Church WB, Sullivan JS. 2012. Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans. Immunol. Cell Biol. 90:149-158.
26. Mathew A, et al. 2011. B-cell responses during primary and secondary dengue virus infections in humans. J. Infect. Dis. 204:1514-1522.
27. Mochizuki Y, et al. 1990. Protection of mice against Sendai virus pneumonia by non-neutralizing anti-F monoclonal antibodies. Microbiol. Immunol. 34:171-183. (Pubitemid 20156333)
28. Monsalvo AC, et al. 2011. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat. Med. 17:195-199.
29. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. 2011. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J. Infect. Dis. 204:1879-1885.
30. Potter CW, Oxford JS. 1979. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35:69-75. (Pubitemid 9096975)
31. Sanofi Pasteur. 2009. Panenza package insert. Sanofi Pasteur, Lyon, France.
32. Sasaki S, et al. 2011. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J. Clin. Invest. 121:3109-3119.
33. Skowronski DM, et al. 2010. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Med. 7:e1000258. doi:10.1371/journal. pmed.1000258.
34. Sun Y, et al. 2010. Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine. PLoS One 5:e14270. doi:10.1371/journal.pone.0014270.
35. Tamura M, Webster RG, Ennis FA. 1994. Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J. Virol. 68:3499-3504. (Pubitemid 24177373)
36. Tecle T, Tripathi S, Hartshorn KL. 2010. Defensins and cathelicidins in lung immunity. Innate Immun. 16:151-159.
37. To KK, et al. 2010. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J. Med. Virol. 82:1-7.
38. To KK, et al. 2010. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis. 50:850-859.
39. To KK, et al. 2010. Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgrad. Med. J. 86:515-521.
40. Tse H, et al. 2011. Structural basis and sequence co-evolution analysis of the hemagglutinin protein of pandemic influenza A/H1N1 (2009) virus. Exp. Biol. Med. (Maywood) 236:915-925.
41. Tse H, et al. 2011. Clinical and virological factors associated with viremia in pandemic influenza A/H1N1/2009 virus infection. PLoS One 6:e22534. doi:10.1371/journal.pone.0022534.
42. Ubol S, Halstead SB. 2010. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin. Vaccine Immunol. 17:1829-1835.
43. Varshney AK, et al. 2011. Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock. J. Biol. Chem. 286:9737-9747.
44. Verma N, et al. 2012. Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 domain) in the elderly than in young adults and children. J. Virol. 86:5515-5522. doi:10.1128/JVI.07085-11.
45. Waffarn EE, Baumgarth N. 2011. Protective B cell responses to flu - no fluke! J. Immunol. 186:3823-3829.
46. Ward JR, Wilson HL, Francis SE, Crossman DC, Sabroe I. 2009. Translational mini-review series on immunology of vascular disease: inflammation, infections and Toll-like receptors in cardiovascular disease. Clin. Exp. Immunol. 156:386-394.
47. Webb SA, et al. 2009. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N. Engl. J. Med. 361:1925-1934.
48. Woo PC, et al. 2004. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet 363:841-845. (Pubitemid 38368831)
49. Yewdell JW. 2010. Monoclonal antibodies specific for discontinuous epitopes direct refolding of influenza A virus hemagglutinin. Mol. Immunol. 47:1132-1136.
50. Yuen KY, et al. 1998. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351:467-471. (Pubitemid 28070092)
51. Zhang AJ, et al. 2011. High incidence of severe influenza among individuals over 50 years of age. Clin. Vaccine Immunol. 18:1918-1924.
52. Zhang R, Rong X, Pan W, Peng T. 2011. Determination of serum neutralization antibodies against seasonal influenza A strain H3N2 and the emerging strains 2009 H1N1 and avian H5N1. Scand. J. Infect. Dis. 43:216-220.
53. Zheng B, et al. 2010. D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Exp. Biol. Med. (Maywood) 235:981-988.